The executive director of the Russian Direct Investment Fund (RDIF), Kirill Dmitriev, said on Saturday that the temporary suspension of candidate trials for the AstraZeneca COVID-19 vaccine clearly showed the “fallacy of approach” when countries “exclusively rely on novel and unproven platforms “when choosing a vaccine to use.
Amid the issue of full compensation by some pharmaceutical companies for any risk of their vaccines by purchasing countries, Dmitriev clarified that Russia will not follow such an approach, as it has demonstrated the safety and efficiency of its platform for human adenoviral vectors, including its Sputnik V.
Praising the benefits of the “Sputnik-V” vaccine, he said that since the vaccine was based on “human adenoviral vectors”, it had been shown to be “safe and effective”.
“We are delighted that AstraZeneca has resumed testing and is continuing to move forward. At the same time, the suspension of the trials clearly showed the fallacy of the approach, when entire countries rely exclusively on new and unproven platforms when choosing a vaccine for widespread use, including the use of a mono adenovirus vector or mRNA technology ” , said. in the statement after AstraZeneca announced that it has resumed trials of the Oxford candidate vaccine that were suspended a few days ago.
“The postponement of the clinical trial also calls into question the request of some of the pharmaceutical companies for full compensation for any risk of their vaccines by the purchasing countries. Russia will not follow that approach, as it has demonstrated the safety and efficiency of its human adenoviral vector platform, including its Sputnik V vaccine, “she added.
AstraZeneca’s coronavirus vaccine phase 3 trials have resumed in the UK, days after they were halted due to safety concerns.
AstraZeneca, a UK-based biopharmaceutical giant, announced on Tuesday that phase 3 testing of its Covid-19 vaccine it is developing with the University of Oxford has been suspended due to a suspected serious adverse reaction in a participant in the United Kingdom. .
The company said the “standard review process triggered a voluntary pause” in all global trials on Sept. 6 so that independent committees and internal regulators could review safety data.
.
